Effects of Cannabis Abstinence on Symptoms and Cognition in Depression
Launched by CENTRE FOR ADDICTION AND MENTAL HEALTH · Aug 7, 2018
Trial Information
Current as of May 13, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ages 18-55
- • meet DSM-5 diagnostic criteria for cannabis use disorder (cannabis use \>1 g/day, CUDIT score \>12)
- • meet DSM-5 diagnostic criteria for Major Depressive Disorder as determined using the SCID
- • be an outpatient receiving a stable dose of antidepressant medication(s) for at least 1 month
- • have a Hamilton Depression Rating Scale (HDRS-17) baseline total score greater than 14
- • have a Full Scale IQ greater than 80 as determined by the WTAR
- • be a non-treatment seeking cannabis user
- • evidence of sufficient motivation and effort as measure by a Test of Memory Malingering (TOMM) score greater than 45
- • urinary baseline THC-COOH levels greater than 150 ng/ml
- Exclusion Criteria:
- • meets criteria for abuse or dependence of alcohol or other illicit substances within the part 6 months (with the exception of cannabis, nicotine, or caffeine)
- • positive urine screen for illicit substances other than cannabis, nicotine or caffeine
- • current suicidal or homicidal ideation
- • psychotic disorder diagnosis (e.g. schizoaffective disorder, major depression with psychotic features) as determined by the SCID
- • head injury with loss of consciousness greater than 2 minutes or requiring hospitalization
- • neurological or medical condition determined to effect cognition
- • be treatment seeking for cannabis use
About Centre For Addiction And Mental Health
The Centre for Addiction and Mental Health (CAMH) is Canada’s leading mental health and addiction teaching hospital, dedicated to advancing research, clinical care, and education in the field of mental health. With a commitment to improving the lives of individuals affected by mental illness and addiction, CAMH conducts innovative clinical trials aimed at developing and evaluating new treatment approaches. The institution fosters a collaborative environment that brings together researchers, clinicians, and community partners to translate scientific findings into effective interventions, ensuring the highest standards of care and support for patients. Through its robust research initiatives, CAMH strives to enhance understanding of mental health disorders and promote evidence-based practices in the treatment of addiction and mental health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Trial Officials
Tony George, M.D., FRCPC
Principal Investigator
Centre for Addiction and Mental Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials